Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3b, double-blind, multicenter, randomized study to compare the efficacy and safety of single dose dalbavancin to a two dose regimen of dalbavancin for the treatment of acute bacterial skin and skin structure infections

Next Previous
Trial Profile

A phase 3b, double-blind, multicenter, randomized study to compare the efficacy and safety of single dose dalbavancin to a two dose regimen of dalbavancin for the treatment of acute bacterial skin and skin structure infections

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Durata Therapeutics

    • Most Recent Events

    • 08 Oct 2017 Results of a subgroup analysis assessing the efficacy and safety of dalbavancin as treatment for ABSSSI in patients with Systemic Inflammatory Response Syndrome, presented at the IDWeek 2017.
    • 08 Oct 2017 Results of post hoc subgroup analysis assessing efficacy of dalbavancin for ABSSSI in patients with and without diabetes presented at the IDWeek 2017
    • 08 Oct 2017 Results of subanalysis assessing efficacy and safety of dalbavancin for the treatment of ABSSSI among overweight and obese patients presented at the IDWeek 2017
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top